Prices delayed by 15 minutes
Next earnings report: 28 October 2026, before market open · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Biogen Inc. trades on Nasdaq under the ticker BIIB. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks BIIB has traded between 138.00 $ and 230.49 $. As of 09 October 2026 the price stood 86.96 % of the way from the 52-week low to the high.
Over one year BIIB shares rose 43.51 %; over six months they rose 23.33 %. Volatility over 90 days is 35.25 %. Dividends are not included: this is price change only, as of 09 October 2026.
BIIB trades at a price-to-earnings ratio of 23.4, below the sector median of 24.8. Price to sales is 3.2, below the sector median of 3.9. Price to book is 1.7, below the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 220.15 | 223.09 | 215.73 | 218.43 | 1M |
| 07 October 2026 | 222.93 | 228.00 | 221.40 | 222.15 | 1M |
| 06 October 2026 | 224.53 | 225.97 | 218.00 | 222.89 | 1M |
| 05 October 2026 | 219.90 | 223.85 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Biogen was built on multiple sclerosis drugs and is making a large bet on treating Alzheimer's disease.
The historical foundation is a range of multiple sclerosis treatments that supplied most of the profit for many years. It is shrinking: patents expired, generics arrived and competitors offered more convenient regimens. That slow contraction defines the company's results.
The replacement is sought in neurology: drugs for Alzheimer's disease and spinal muscular atrophy. The Alzheimer's line proved hard — the first approved drug was withdrawn after disputes over whether the effect was demonstrated, and the second is advancing slowly because it requires diagnosis and monitoring the health system is not equipped for. The company pays no dividend.
Address:225 BINNEY STREET, CAMBRIDGE, MA, 02142, US
Biogen Inc. reported revenue of 9.9B $ and net income of 1.4B $ over the last four quarters. Net margin is 13.81 %. Revenue changed by +1.23 % year over year. Earnings per share are 9.30 $. Market capitalisation is 32.1B $.
BIIB has a return on equity of 7.36 %, above the sector median of −41.68 %. Return on assets is 4.65 %, above the sector median of −32.11 %.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 111.70 | +1.69 % | 251M |
| TECHBio-Techne Corp | 72.46 | +0.01 % | 215M |
| KODKodiak Sciences Inc | 99.25 | +5.29 % | 214M |
| 218.22 |
| 223.59 |
| 951,300 |
| 02 October 2026 | 222.98 | 224.08 | 219.81 | 219.88 | 779,900 |
| 01 October 2026 | 225.50 | 228.31 | 222.50 | 222.82 | 2M |
| 30 September 2026 | 227.23 | 229.36 | 225.51 | 225.88 | 2M |
| 29 September 2026 | 227.02 | 229.41 | 224.45 | 227.07 | 1M |
| 28 September 2026 | 225.87 | 230.49 | 225.51 | 228.69 | 1M |
| 25 September 2026 | 228.27 | 228.92 | 223.76 | 227.60 | 958,000 |
| 24 September 2026 | 226.80 | 228.72 | 224.31 | 226.36 | 1M |
| 23 September 2026 | 226.94 | 229.19 | 222.36 | 227.53 | 1M |
| 22 September 2026 | 219.22 | 226.43 | 219.00 | 225.36 | 1M |
| 21 September 2026 | 216.14 | 221.92 | 214.59 | 219.07 | 928,500 |
| 18 September 2026 | 219.05 | 220.17 | 215.26 | 215.50 | 3M |
| 17 September 2026 | 217.68 | 219.41 | 215.33 | 219.05 | 836,700 |
| 16 September 2026 | 216.41 | 218.29 | 214.81 | 216.01 | 606,500 |
| 15 September 2026 | 216.71 | 216.71 | 213.54 | 216.17 | 756,000 |
| 14 September 2026 | 221.00 | 222.25 | 215.56 | 217.36 | 629,900 |
| 11 September 2026 | 216.75 | 219.76 | 214.71 | 217.15 | 1M |